Elevance Health Inc., a leading US health insurance provider, has shown robust growth over the past five years, with a 21.9% cumulative return for investors, outpacing the S&P 500 index, and a projected 13% upside over the next 12 months, according …

West Pharmaceutical Services Inc. is facing a downturn in its share price due to financial, regulatory, and competitive challenges, including margin compression, FDA scrutiny, and a lack of innovation in its product pipeline, but a focused strategy …

Vertex Pharmaceuticals Inc. is a long-term performer with a strong track record of outpacing the broader market, driven by its robust operational discipline, pipeline growth, and pricing power, but faces risks such as patent expirations, regulatory …

Pro Medicus Ltd, an Australian health-tech provider, has secured a €10 million, five-year contract with University Hospital Heidelberg and the German Cancer Research Institute, marking a significant expansion into the European market and positioni…

BioMarin Pharmaceutical Inc. has experienced a decline in its share price over the past five years, but its robust pipeline of enzyme replacement therapies for rare genetic disorders and strategic regulatory engagements position it favorably within …

Alnylam Pharmaceuticals Inc. is poised to capitalize on the growing rare-disease therapeutics market, with a robust pipeline, strong analyst sentiment, and favorable market conditions, despite operational challenges and reimbursement complexities.

Cooper Cos Inc-The maintains a stable financial profile and operational status, with no significant changes or catalysts for disruption, despite broader industry developments in healthcare equipment and supplies.

Galderma Group AG, a specialist in dermatological therapeutics, has reported a modest share price uptick, driven by solid fundamentals and a diversified pricing strategy, but faces patent expiration risks and must navigate market constraints to sust…

Edwards Lifesciences Corp. faces a complex landscape of regulatory scrutiny, intensifying competition, and shifting clinical preferences, which may impact its growth trajectory and valuation, as investors await the company’s next earnings report.

Siemens Healthineers AG navigates a complex landscape of growth opportunities and challenges in the medical technology sector, driven by factors such as regulatory changes, competition, and emerging trends in tele-diagnostics and sustainability.